Masoud Azodi, MD
Emeritus FacultyCards
Additional Titles
Director of Minimally Invasive and Robotic Surgery, Director of Minimally Invasive Gynecologic Surgery Fellowship
Contact Info
Obstetrics, Gynecology & Reproductive Sciences
PO Box 208063
New Haven, CT 06520-8063
United States
About
Copy Link
Titles
Emeritus Faculty
Director of Minimally Invasive and Robotic Surgery, Director of Minimally Invasive Gynecologic Surgery Fellowship
Biography
Dr. Masoud Azodi has been at Yale for almost 20 years. He’s honored to be a part of the Ob/Gyn department where, he says, “we have excellent patient care and our team works with up-to-date surgical techniques and research.”
Dr. Azodi completed his undergraduate, graduate, medical school and Ob/Gyn residency training in Ohio. He then completed his fellowship in Gynecologic Oncology at Yale School of Medicine (YSM) in 1996. He is currently a professor in the department of Obstetrics, Gynecology and Reproductive Sciences at YSM. He is director of minimally invasive and robotic surgery and director of minimally invasive gynecologic surgery fellowship program in gynecologic oncology section.
Dr. Azodi is board certified in both Ob/Gyn and in Gynecologic Oncology. He treats all gynecologic cancers and pre-cancers using numerous therapies, including chemotherapy and surgery. Dr. Azodi has a special interest in minimally invasive surgical techniques, particular robotic surgery and its future in medicine. He has performed many minimally invasive surgeries for management of gynecologic diseases, including more than 2,500 conventional laparoscopic and more than 2,000 robotic-assisted cases.
On the clinical side, Azodi’s interests include pre-malignant and malignant gynecologic disorders involving the vulva, cervix, vagina, uterus, ovaries and placenta. In addition to helping women with cervical cancer explore less-invasive treatment options, Dr. Azodi educates his patients on radical trachelectomy: a surgical option that removes the cervix, upper part of the vagina and lymph nodes in the pelvis. This treatment plan can be helpful for patients concerned with maintaining their fertility after cancer.
Dr. Azodi was named as a “Top Doc” in New York magazine’s “Best Doctors” of 2012, 2013, and 2014. He is the editor-in-chief of the international journal Robotic Surgery: Research and Reviews. He also serves on the editorial board of several other peer-reviewed journals.
Dr. Azodi is actively involved in research and is a principal investigator (PI) and co-PI in multiple protocols treating gynecologic cancer. He also trains residents and fellows in gynecologic cancer treatment and in performing minimally invasive surgeries for complicated gynecologic disorders.
Appointments
Obstetrics, Gynecology & Reproductive Sciences
EmeritusPrimary
Other Departments & Organizations
- Developmental Therapeutics
- Discovery to Cure
- Gynecologic Oncology Program
- Hepatic Arterial Infusion (HAI) Program
- Hyperthermic intraperitoneal chemotherapy (HIPEC) Program
- Obstetrics, Gynecology & Reproductive Sciences
- Oligometastatic Cancer Program
- Ovarian Cancer Early Detection Program
- Yale Cancer Center
- Yale Ventures
Education & Training
- Fellowship
- Yale University School of Medicine (1999)
- Residency
- Aultman Hospital/Neoucom (1996)
- MD
- Wright State University (1992)
Board Certifications
Gynecologic Oncology
- Certification Organization
- AB of Obstetrics & Gynecology
- Latest Certification Date
- 2022
- Original Certification Date
- 2002
Obstetrics & Gynecology
- Certification Organization
- AB of Obstetrics & Gynecology
- Latest Certification Date
- 2022
- Original Certification Date
- 2000
Research
Copy Link
Overview
Please see PubMed for publications.
Medical Research Interests
ORCID
0000-0002-0570-8089
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Alessandro Santin, MD
Pei Hui, PhD, MD
Gloria Huang, MD, FACOG
Stefania Bellone, PhD
Mitchell Clark, MD, MPH
Natalia Buza, MD
Laparoscopy
Cerclage, Cervical
Sarcoma, Endometrial Stromal
Fertility Preservation
Medical Oncology
Publications
2025
Adverse events beyond the RUBY trial: reporting immunotherapy-associated myocarditis, myositis, and myasthenia gravis in a real-world endometrial cancer case
Abozenah Y, McNamara B, Greenman M, Daigle E, Mikhaiel J, DiCapua D, Kwan J, Azodi M, Altwerger G. Adverse events beyond the RUBY trial: reporting immunotherapy-associated myocarditis, myositis, and myasthenia gravis in a real-world endometrial cancer case. Gynecologic Oncology Reports 2025, 61: 101950. DOI: 10.1016/j.gore.2025.101950.Peer-Reviewed Original ResearchCitationsConceptsLife-threatening complicationsMyasthenia gravisImmune checkpoint inhibitor (ICI)-associated myocarditisComplication of ICI therapyPositive acetylcholine receptor antibodyHigh-dose steroidsTreated with carboplatinEndometrial cancer casesAcetylcholine receptor antibodiesDiagnosis of myocarditisElevated creatine kinaseCritical care managementICI therapyElevated troponinBilateral ptosisEndometrial adenocarcinomaReceptor antibodiesCardiac symptomsTherapeutic challengeMultidisciplinary managementRespiratory compromiseCardiac MRIAdverse eventsCancer casesDostarlimabFertility preserving, uterine sparing approach to a uterine extragonadal yolk sac tumor
Greenman M, McNamara B, Ettorre V, Buza N, Azodi M. Fertility preserving, uterine sparing approach to a uterine extragonadal yolk sac tumor. Gynecologic Oncology Reports 2025, 59: 101778. PMID: 40585380, PMCID: PMC12205314, DOI: 10.1016/j.gore.2025.101778.Peer-Reviewed Original ResearchConceptsExtragonadal yolk sac tumorYolk sac tumorSac tumorUterine preservationSpontaneously conceived pregnanciesFertility preservation strategiesYoung womenDegenerating fibroidsNegative marginsWedge resectionSurgical approachStaging procedureTreatment optionsTumorCompleted childbearingRecurrencePatientsWomenReproductive goalsObjective treatmentTreatmentHysterectomyFibroidsMyometriumChemotherapyThe Multidisciplinary Management of a Patient With Infected Iliocaval Stents and Uterine Cancer Invasion
Said S, Gu E, Li A, Loh S, Mojibian H, Azodi M, Chaar C. The Multidisciplinary Management of a Patient With Infected Iliocaval Stents and Uterine Cancer Invasion. Journal Of Vascular Surgery Venous And Lymphatic Disorders 2025, 13: 102135. DOI: 10.1016/j.jvsv.2024.102135.Peer-Reviewed Original ResearchVascular segmental exclusion for recurrent vulvar squamous cell carcinoma invading the femoral vessels
Schwartz A, Azodi M, Cardella J, Chaar C. Vascular segmental exclusion for recurrent vulvar squamous cell carcinoma invading the femoral vessels. Journal Of Vascular Surgery Cases And Innovative Techniques 2025, 11: 101753. PMID: 40207260, PMCID: PMC11981742, DOI: 10.1016/j.jvscit.2025.101753.Peer-Reviewed Original ResearchCitationsConceptsRecurrent vulvar squamous cell carcinomaVulvar squamous cell carcinomaInvasive vulvar carcinomaExtensive local invasionProgression of oncological diseasesSquamous cell carcinomaLower limb ischemiaSuperficial femoral arteryVulvar carcinomaFemoral artery embolismAbdomen-pelvisUnresectable tumorsArtery embolizationCell carcinomaLeft axillaryPopliteal artery bypassWide resectionThree-month follow-upLocal invasionArtery bypassComputed tomographyFollow-upNecrotic massLimb ischemiaFemoral vein
2024
Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer: Updated survival and subgroup analyses
Roque D, Siegel E, Buza N, Bellone S, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Xu F, Hui P, Altwerger G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer: Updated survival and subgroup analyses. Gynecologic Oncology 2024, 190: s299-s301. DOI: 10.1016/j.ygyno.2024.07.449.Peer-Reviewed Original ResearchTrastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2
Mutlu L, McNamara B, Bellone S, Manavella D, Demirkiran C, Greenman M, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Clinical & Experimental Metastasis 2024, 41: 765-775. PMID: 38909139, DOI: 10.1007/s10585-024-10297-z.Peer-Reviewed Original ResearchCitationsConceptsHigh-grade serous ovarian cancerClear cell carcinomaHER2-targeting antibody-drug conjugateAntibody-drug conjugatesT-DXdReceptor over-expressionTrastuzumab deruxtecanXenograft modelCell linesOvarian clear cell carcinomaOvarian cancer cell linesTumors overexpressing HER2Biologically aggressive tumorsFluorescence in situ hybridization assaySerous ovarian cancerEffective antibody-drug conjugatesIn vivo antitumor activityMouse xenograft modelMetastatic cell linesDS-8201aCancer cell linesAggressive tumorsHER2 expressionCell carcinomaOvarian cancerRandomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses
Roque D, Siegel E, Buza N, Bellone S, Huang G, Altwerger G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses. BJC Reports 2024, 2: 43. PMID: 39516558, PMCID: PMC11523995, DOI: 10.1038/s44276-024-00067-5.Peer-Reviewed Original ResearchConceptsPre-treated ovarian cancerOverall survivalBev armsDose reductionOvarian cancerTaxane responseRandomized phase 2 trialRandomized phase II trialPaclitaxel-resistant diseaseResultsThirty-seven patientsTreated with paclitaxelPhase 2 trialBiweekly bevacizumabDays 1,8,15Taxane-sensitiveUpdate survivalProgression-FreePeritoneal cancerDose modificationTaxane sensitivityPlatinum resistanceSubset analysisSubgroup analysisResponse ratePatientsIntegrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix
Bellone S, Jeong K, Halle M, Krakstad C, McNamara B, Greenman M, Mutlu L, Demirkiran C, Hartwich T, Yang-Hartwich Y, Zipponi M, Buza N, Hui P, Raspagliesi F, Lopez S, Paolini B, Milione M, Perrone E, Scambia G, Altwerger G, Ravaggi A, Bignotti E, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Quick C, Angioli R, Terranova C, Zaidi S, Nandi S, Alexandrov L, Siegel E, Choi J, Schlessinger J, Santin A. Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2321898121. PMID: 38625939, PMCID: PMC11046577, DOI: 10.1073/pnas.2321898121.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsWhole-exome sequencingPatient-derived-xenograftsBase excision repairCopy number lossMultiregion whole-exome sequencingCopy number gainHigh-grade neuroendocrine carcinomaCNV analysisPhylogenetic analysisEvolutionary historyNeuroendocrine cervical cancerHuman papillomavirus DNAMutator phenotypeSensitivity to afatinibGenetic landscapeRecurrent mutationsRNA sequencingGene fusionsMutational landscape analysisExcision repairGenesMutationsPan-HERConsistent with deficiencyNeuroendocrine carcinomaRandomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsRandomized phase II trialCD4/CD8 T cellsT cellsHPV clearanceArm BNo significant differenceClinical surveillanceRate of HPV clearanceSecondary outcomesPre-neoplastic cervical lesionsCervical intraepithelial neoplasiaT cell infiltrationT cell responsesSignificant differenceCIN3 patientsIntraepithelial neoplasiaArm ACervical lesionsImiquimod groupSurveillance armVaginal suppositoriesProspective trialsArm CHPV vaccinationImiquimodCorrection: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
Roque D, Siegel E, Buza N, Bellone S, Silasi D, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Reader J, Hui P, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin A. Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British Journal Of Cancer 2024, 130: 1073-1073. PMID: 38438590, PMCID: PMC10951353, DOI: 10.1038/s41416-024-02628-4.Peer-Reviewed Original ResearchCitationsAltmetric
News & Links
Copy Link
Media
News
- May 09, 2025
16 Yale Ob/Gyn Physicians Named "Top Doctors" for 2025
- November 07, 2024
Yale Ob/Gyn Faculty Present the Latest in Gynecologic Oncology at Memorial Conference
- May 02, 2024
15 Yale Ob/Gyn Physicians Named "Top Doctors" For 2024
- April 15, 2024
Genetic Analysis of Rare, Often Deadly Cervical Cancer Uncovers Potential Treatments
Get In Touch
Copy Link
Contacts
Obstetrics, Gynecology & Reproductive Sciences
PO Box 208063
New Haven, CT 06520-8063
United States
Administrative Support
Locations
Yale Obstetrics, Gynecology & Reproductive Sciences
Academic Office
Farnam Memorial Building
310 Cedar Street, Wing Gynecologic Oncology, Fl 3rd, Ste 328E
New Haven, CT 06510
General Information
203.785.4013Fax
203.785.4135